Harmony Biosciences Holdings, Inc. HRMY Debt-to-equity

Debt-to-equity at other companies

Jazz PharmaceuticalsJAZZ

1.2×-0.1×

AlkermesALKS

0.9×+0.8×

Axsome TherapeuticsAXSM

4×+0.1×

Stoke Therapeutics, Inc.STOK

0×0.0×

Amneal Pharmaceuticals, Inc.AMRX

77.8×—

Acadia PharmaceuticalsACAD

0.1×0.0×

FAQ

What is Harmony Biosciences Holdings, Inc.'s debt-to-equity?

Harmony Biosciences Holdings, Inc. (HRMY) reported debt-to-equity of 0.2× in Q1 2026.

How has Harmony Biosciences Holdings, Inc.'s debt-to-equity changed year-over-year?

Harmony Biosciences Holdings, Inc.'s debt-to-equity decreased by 26.6% year-over-year, from 0.2× to 0.2×.

What is the long-term trend for Harmony Biosciences Holdings, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s debt-to-equity has grown at a -37.2% compound annual growth rate (CAGR), from 2× to 0.2×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.